Results 61 to 70 of about 859,289 (399)
Cancers, 2021 Simple Summary Due to the approval of immune checkpoint inhibitor therapy for microsatellite instability-high or mismatch repair-deficient advanced solid tumors, testing of both biomarkers has gained interest in recent years.
J. Siemanowski +10 more
semanticscholar +1 more source
Molecular testing of soft tissue tumors
Diagnostic Cytopathology, Volume 51, Issue 1, Page 12-25, January 2023., 2023 Abstract Background The diagnosis of soft tissue tumors is challenging, especially when the evaluable material procured is limited. As a result, diagnostic ancillary testing is frequently needed. Moreover, there is a trend in soft tissue pathology toward increasing use of molecular results for tumor classification and prognostication. Hence, diagnosing
Douglas Rottmann +2 more
wiley +1 more source
3 '-UTR poly(T/U) repeat of EWSR1 is altered in microsatellite unstable colorectal cancer with nearly perfect sensitivity [PDF]
, 2015 Approximately 15 % of colorectal cancers exhibit instability of short nucleotide repeat regions, microsatellites. These tumors display a unique clinicopathologic profile and the microsatellite instability status is increasingly used to guide clinical ...
Aaltonen, Lauri A. +11 more
core +1 more source
No evidence of EMAST in whole genome sequencing data from 248 colorectal cancers [PDF]
, 2021 Microsatellite instability (MSI) is caused by defective DNA mismatch repair (MMR), and manifests as accumulation of small insertions and deletions (indels) in short tandem repeats of the genome. Another form of repeat instability, elevated microsatellite
Aaltonen, Lauri A. +14 more
core +1 more source
Annals of Oncology, 2019 BACKGROUND Cancers with a defective DNA mismatch repair (dMMR) system contain thousands of mutations most frequently located in monomorphic microsatellites and are thereby defined as having microsatellite instability (MSI).
C. Luchini +10 more
semanticscholar +1 more source
Hepatology, EarlyView., 2022 Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou +13 more
wiley +1 more source
Clinical Cancer Research, 2019 The FDA approved pembrolizumab on May 23, 2017, for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H), or mismatch repair deficient (dMMR) solid tumors that have progressed following ...
L. Marcus +3 more
semanticscholar +1 more source
Theranostics, 2020 Microsatellite instability (MSI) has been approved as a pan-cancer biomarker for immune checkpoint blockade (ICB) therapy. However, current MSI identification methods are not available for all patients.
Rui Cao +19 more
semanticscholar +1 more source
Systemic circulating microRNA landscape in Lynch syndrome
International Journal of Cancer, Volume 152, Issue 5, Page 932-944, 1 March 2023., 2023 What's new? Systemic circulating microRNA expression patterns (c‐miRnomes) are altered during sporadic carcinogenesis and they have predictive potential in early cancer detection. However, their potential in carriers of inherited pathogenic mismatch‐repair gene variants associated with Lynch syndrome remains understudied.
Tero Sievänen +10 more
wiley +1 more source
BMC Cancer, 2022 Background As a transmembrane protein, C-type lectin-like receptor 2 (CLEC-2) is mainly expressed on platelets and released into plasma after platelet activation. Activated platelets participate in the regulation of innate immune cells.
Xin Zhang +5 more
doaj +1 more source